Author:
Tewari Krishnansu,Manetta Alberto
Publisher
Springer Science and Business Media LLC
Reference53 articles.
1. Advanced Ovarian Cancer Trialist Group: Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials. Br Med J 1991, 303:884–93.
2. Ovarian Cancer Meta-analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy in ovarian carcinoma: a metaanalysis. J Clin Oncol 1991, 9:1668–1674.
3. Levin L, Simon R, Hryniuk W: Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis. J Natl Cancer Inst 1993, 85:1732–1742.
4. McGuire WP, Hoskins WJ, Brady MF, et al.: Cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996, 334:1–6.
5. Sood AK and Buller RE: Drug resistance in ovarian cancer: From the laboratory to the clinic. Obstet Gynecol 1998, 92:312–319. An excellent, concise review of the molecular biology associated with antineoplastic drug resistance.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献